TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05528146

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Psyllium huks
Description: psyllium in 250ml of water

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Psyllium huks
Description: psyllium in 250ml of water
Study: NCT06335472

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 3 nerves pulsed radiofrequency with hydrodissection
Description: Patient will be in a sitting position, targeting the SSN, needle will be pushed towards floor of the suprascapular fossa, SSN is just adjacent to the suprascapular artery.~The axillary nerve, between the deltoid muscle posteriorly, triceps muscle caudally and humerus anteriorly, axillary nerve appears as hyperechoic round in relation to posterior circumflex humeral artery.~Lateral pectoral nerve, middle of coracoid process should be targeted, lie within hyperechoic fascial plane between pectoralis major and pectoralis minor muscle.~hydrodissection, US transducer will be positioned inferior to scapular line , landmarks are contours of glenoid rim and humeral head, needle will be advanced until enter the GHJ capsule.~A solution composed of 3 mL of lidocaine 1%, 3 mL of bupivacaine 0.25%, and 1 mL of dexamethasone 40 mg, followed by infusion of up to 40 mL of normal saline, until capsule is adequately distended and resistance felt

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: suprascapular nerve pulsed radiofrequency with hydrodissection
Description: The patient will be positioned in a sitting position, PRF needle will be pushed forward towards the floor of the suprascapular fossa the SSN will be visualized just adjacent to the suprascapular artery.~hydrodissection will be done under all aseptic measures ,the US transducer will be positioned just inferior to the scapular line , landmarks are contours of posterior glenoid rim and humeral head, needle will be advanced until the needle tip will enter the GHJ capsule.~A solution composed of 3 mL of lidocaine 1%, 3 mL of bupivacaine 0.25%, and 1 mL of dexamethasone 40 mg, followed by an infusion of up to 40 mL of normal saline , until the capsule is adequately distended and resistance will be felt.
Study: NCT06461871

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BALANCE TRAINING WITH MODERATE INTESITY AEROBIC VERSUS RESISTED TRAINING (RT)
Description: The duration of study is 6 months. Three to five sessions of both aerobic and resistance exercise training in combination with balance training are taken out per week . Each session lasting 15 minutes. GROUP A: Baseline treatment + Moderate intensity aerobic exercises in combination with balance training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BALANCE TRAINING WITH MODERATE INTESITY AEROBIC VERSUS RESISTED TRAINING (RT)
Description: The duration of study is 6 months. Three to five sessions of both aerobic and resistance exercise training in combination with balance training are taken out per week . Each session lasting 15 minutes. GROUP A: Baseline treatment + Moderate intensity aerobic exercises in combination with balance training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate intensity resistance exercises in combination with balance training
Description: The duration of study is 6 months. Three to five sessions of both aerobic and resistance exercise training in combination with balance training are taken out per week . Each session lasting 15 minutes. GROUP B: Baseline treatment + Moderate intensity resistance exercises in combination with balance training
Study: NCT05237180

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: spatial localisation training
Description: 8 spatial localization training sessions MBAA and SSQ tests before and after training sessions.
Study: NCT06241287

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Better Living with Non-memory led Dementia programme
Description: an 8-week duration 6-module educational programme covering the following topics: 1) Welcome to the programme and what to expect from it; 2) Understanding the disease; 3) How to provide better support for the person with dementia; 4) How to look after the caregiver's own mental health; 5) Where to find additional sources of support, and 6) An introduction to the value of support groups. At the end of modules 2, 3, and 4, participants will be asked to complete a real-life task to put in practice skills learned in the specific module (e.g., approaching a friend and explaining the disease in lay terms). The first session (onboarding) will be facilitated via Zoom by one of the members of the research team. Up to 3 total interactions between facilitators and participants will be offered to support participants' engagement with the programme. All course modules will be printable using the pdf download button on the programme's page.

Intervention type: OTHER
Group type: OTHER
Intervention: Waiting list
Description: Signposting individuals to the publicly available Rare Dementia Support website. The control group will further receive access to the Better Living with Non-memory led Dementia programme after completing the collection of measures at 6 months.
Study: NCT04986020

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: Identification of novel biomarkers from MRI

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: Identification of novel biomarkers from MRI
Study: NCT06461871

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate intensity resistance exercises in combination with balance training
Description: The duration of study is 6 months. Three to five sessions of both aerobic and resistance exercise training in combination with balance training are taken out per week . Each session lasting 15 minutes. GROUP B: Baseline treatment + Moderate intensity resistance exercises in combination with balance training
Study: NCT06231719

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manuel Pressure
Description: Using manuel pressure ( about 10 second ) before the Anti-D immunglobulin injection.
Study: NCT04899713

Intervention type: OTHER
Intervention: Survival survey
Description: To assess the effect of adding ZOMETA® to neoadjuvant chemotherapy on event-free survival.

Intervention type: OTHER
Intervention: Survival survey
Description: To assess the effect of adding ZOMETA® to neoadjuvant chemotherapy on event-free survival.
Study: NCT05902819

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Imagery
Description: Guided imagery of personal trauma- or cocaine-related memory approximately 120min after study medication was given.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Imagery
Description: Guided imagery of personal trauma- or cocaine-related memory approximately 120min after study medication was given.
Study: NCT06231719

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard Injection Procedure
Description: Using any special method for injection
Study: NCT06525922

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Center M
Description: Center M consists of weekly, 1-hour, telehealth, mindfulness-based Cognitive Behavioral Therapy (CBT) group sessions for four consecutive weeks. Participants joined group sessions on their personal computer, tablet, or phone. Each visit involved the introduction of a core mental well-being theme, learning skills to develop non-judgmental self-awareness and/or cognitive reappraisal skills, skills practice, and discussion of home practice materials. Home practice materials included written mindful awareness instructions, audio-guided meditations, self-compassion exercises, and practices in recognizing the interrelationships between thoughts, feelings, and behaviors.
Study: NCT05902819

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Imagery
Description: Guided imagery of personal trauma- or cocaine-related memory approximately 120min after study medication was given.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Imagery
Description: Guided imagery of personal trauma- or cocaine-related memory approximately 120min after study medication was given.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: Single dose of minocycline (200mg) at each of two imagery sessions; Minocycline is given orally in form of a capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: Single dose of minocycline (200mg) at each of two imagery sessions; Minocycline is given orally in form of a capsule.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose of mannitol (100%) at each of two imagery sessions; Placebo is given orally in form of a capsule.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose of mannitol (100%) at each of two imagery sessions; Placebo is given orally in form of a capsule.
Study: NCT04807751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delgocitinib cream
Description: Cream for topical application

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Delgocitinib cream vehicle
Description: The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.
Study: NCT05763706

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multiwave Locked System® (M6 laser, ASA srl, Arcugnano (VI), Italy)
Description: MLS® Laser M6 is a PBM device that allows the patients to be treated in various positions, either sitting, lying down or at a distance, without risk of contamination. Treatment times are carefully calibrated to deliver the best possible energy dose to the tissue being treated.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multiwave Locked System® (M6 laser, ASA srl, Arcugnano (VI), Italy)
Description: MLS® Laser M6 is a PBM device that allows the patients to be treated in various positions, either sitting, lying down or at a distance, without risk of contamination. Treatment times are carefully calibrated to deliver the best possible energy dose to the tissue being treated.
Study: NCT04896034

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MILTA Device
Description: Patients in MILTA Device group will each receive 2 sessions of PBM in this study, the first session within 24 hours of delivery, and the second session 24 hours after the first session.
Study: NCT05636202

Intervention type: OTHER
Intervention: No intervention
Description: There was no intervention in the retrospective study

Intervention type: OTHER
Intervention: No intervention
Description: There was no intervention in the retrospective study
Study: NCT05952050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Different Administration Routes of Dexmedetomidine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Different Administration Routes of Dexmedetomidine
Study: NCT05558995

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ketogenic diet
Description: All the subjects will be instructed by a nutrition professional to have at least 3 meals per day consisting of 20 g to 30 g of carbohydrate in the form of green vegetables and salad, and 80 g to 100 g of protein in the form of meat, fish, fowl, eggs, shellfish and cheese for 12 weeks. Polyunsaturated and monounsaturated fats will also be included in the diet. Micronutrients (vitamins and minerals) will be given to each subject in the form of one capsule per day. The adherence to diet will be confirmed weekly through a food log and urinary ketones assessment using dipstick to ensure that all individuals remain in a ketotic state.
Study: NCT06303713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Platinum coordination compound, premixed aqueous solution of 10mg/ML, via intravenous (into the vein) infusion per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Platinum coordination compound, premixed aqueous solution of 10mg/ML, via intravenous (into the vein) infusion per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-PSMA-617
Description: Radioligand therapy, single-dose vial, via intravenous (into the vein) infusion per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-PSMA-617
Description: Radioligand therapy, single-dose vial, via intravenous (into the vein) infusion per protocol.
Study: NCT05266079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intervention Group
Description: Gan Mai Bai He Di Hung Tang, Tian Wang Bu Xin Dan,Shugan Granules,Liu Wei Di Huang Pill and Er Zhi Pill , You Gui pill and Li Zhong pill addition and subtraction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Control Group
Description: Er-Xian decoction
Study: NCT05673213

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Three-stair positioning pillows group
Description: The infant was cared for, fed and treated by the primary nurse responsible for the infant between 08:30 and 08:55. No intervention was made to the preterm infant between 09:00-12:00 and the infant was allowed to rest. Preterm infants were followed for 3 hours (09:00-12:00) with three-stair positioning pillows. Between these hours, the oxygen saturation and heart rate of the preterm infants in were counted by the researcher with a pulse oximeter device and recorded 18 times in 10 minutes. Sleep-wakefulness status was recorded by taking 15-second recordings with the Actigraphy measuring device.
Study: NCT05963191

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Colorectal cancer screening with CAD EYE colonoscopy
Description: The colonoscopy procedure for each patient will be no different from a conventional colonoscopy examination. A colonoscopy is considered complete if the endoscope reaches the appendicular orifice or the terminal ileum. In line with recommendations, water lavage (using a lavage pump) and aspiration of food residues will be performed on ascent and/or descent to visualize the entire colonic mucosa.~In the CAD EYE group, descent is performed under white light, with the CAD EYE system switched on. When polyps are detected, they are rigorously described and histological predictions of endoscopist and CAD EYE will be reported separately. Then polyps will be removed by polypectomy or mucosectomy. Removed polyps are then sent for anatomopathological analysis.
Study: NCT05120323

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: vDOT Intervention Group
Description: The vDOT intervention group will submit video clips of doses of inhaled controller asthma medication via the Emocha® smartphone application with each prescribed dose of inhaled controller medication. Each video will include a date and time stamp of the medication dose. Participant videos will be evaluated by trained personnel using an inhaler technique checklist to score each dose and create a report detailing the steps that were taken to complete the medication dose.
Study: NCT06070974

Intervention type: DIAGNOSTIC_TEST
Intervention: CMR and blood collection
Description: All patients enrolled will undergo 2 CMR examination (within 3-5 days post PCI and after six months), and blood collection at third day after PCI (T0). Patients recruited at Centro Cardiologico Monzino will be subjected to a blood withdrawal also at different time points: 1- 3- 6 months after STEMI (T1, T2, and T3 respectively).
Study: NCT04968483

Intervention type: OTHER
Intervention: Data collection
Description: The general data, data of postoperative complications, data of nutritional assessment and nutritional support will be collected.
Study: NCT05393700

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Action Observation Therapy
Description: Action Observation Therapy implies the observation of video-clips representing motor tasks alone or followed by imagination and/or imitation of observed tasks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Action Observation Therapy
Description: Action Observation Therapy implies the observation of video-clips representing motor tasks alone or followed by imagination and/or imitation of observed tasks.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Action Observation Therapy
Description: Action Observation Therapy implies the observation of video-clips representing motor tasks alone or followed by imagination and/or imitation of observed tasks.
Study: NCT04843631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BFI-751
Description: Single use vial, solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EU-STELARA®
Description: Pre-filled syringe, solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: US-STELARA®
Description: Pre-filled syringe, solution
Study: NCT04896034

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention:  control 1  fake MILTA device
Description: Patients in group control 1 will each receive 2 sessions of PBM in this study, the first session within 24 hours of delivery, and the second session 24 hours after the first session.
Study: NCT05187975

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture:~Scalp acupuncture includes middle line of forehead (MS1), a front line by the forehead (MS2), and middle line of vertex (MS5), these acupoints are needled for 1 inch with the direction with scalp tilted 15-30 degrees.~Body acupuncture includes Yintang (DU29), Taichong (LR3), Shenmen (HT7), Neiguan (PC6), Danzhong (RN17), Qimen (LR14), Taixi (KI3).~Traditional Chinese medicine:~Chaihushugan Power: Chaihu 12g, Chenpi 12g, Chuanxiong 9g, vinegar Xiangfu 9g, Zhike 9g, Shaoyao 9g, roasted Gancao 3g.~Repetitive transcranial magnetic stimulation:~The CCY-I magnetic field stimulator from Wuhan Irid Medical Equipment New Technology Co is used, with a frequency of 10Hz.~Standard care:~The same as the standard care group.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Acupuncture:~Scalp acupuncture includes middle line of forehead (MS1), a front line by the forehead (MS2), and middle line of vertex (MS5), these acupoints are needled for 1 inch with the direction with scalp tilted 15-30 degrees.~Body acupuncture includes Yintang (DU29), Taichong (LR3), Shenmen (HT7), Neiguan (PC6), Danzhong (RN17), Qimen (LR14), Taixi (KI3).~Traditional Chinese medicine:~Chaihushugan Power: Chaihu 12g, Chenpi 12g, Chuanxiong 9g, vinegar Xiangfu 9g, Zhike 9g, Shaoyao 9g, roasted Gancao 3g.~Repetitive transcranial magnetic stimulation:~The CCY-I magnetic field stimulator from Wuhan Irid Medical Equipment New Technology Co is used, with a frequency of 10Hz.~Standard care:~The same as the standard care group.
Study: NCT05997966

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Progresive Resistance Exercises
Description: At the beginning of the study, there will be a home visit (week 0) where the exercises will be taught. Exercise brochures explaining the exercises in written and visual form will also be given to each participant during the first and subsequent home visits. After the first home visit, individuals will be asked to keep an exercise diary prepared by the physiotherapist in order to control the exercises, the occurrence of side effects and dependence on the treatment, and information will be obtained from the individuals by phone calls every week. Two more home visits will take place in weeks 5 and 9 to further the IDE program. Apart from these visits and phone calls, the participant will be allowed to call the physiotherapist if needed. In the exercise group, the 12-week home-based IDE program will be applied 2 sets/day for 3 days/week (on non-consecutive days).

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: No intervation
Description: After a general education about osteoarthritis in the control group, 30 minutes of walking will be requested twice a week, and no other intervention will be made.
Study: NCT05931055

Intervention type: DIAGNOSTIC_TEST
Intervention: Fragmentomics
Description: The fragmentation patterns of cfDNA fragments in plasma and the uneven coverage of the genome can indirectly reflect the state of gene expression regulation in vivo. Its characteristics mainly include copy number variation (CNV), Nucleosome footprint, fragment length and motif. Fragomics relies on WGS (Whole Genome Sequencing), and the target covers the whole Genomics level. Thus, the cfDNA Fragmentomics testing can help differentiation and early diagnosis.

Intervention type: DIAGNOSTIC_TEST
Intervention: Fragmentomics
Description: The fragmentation patterns of cfDNA fragments in plasma and the uneven coverage of the genome can indirectly reflect the state of gene expression regulation in vivo. Its characteristics mainly include copy number variation (CNV), Nucleosome footprint, fragment length and motif. Fragomics relies on WGS (Whole Genome Sequencing), and the target covers the whole Genomics level. Thus, the cfDNA Fragmentomics testing can help differentiation and early diagnosis.
Study: NCT06033365

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: care navigation
Description: Dedicated care navigation throughout study enrollment and follow-up period. Care navigation consists of addressing social support needs (e.g. transportation, communication, housing).
Study: NCT05566548

Intervention type: DIAGNOSTIC_TEST
Intervention: Liquid Chromatography-Mass Spectrometry Method to identify bilirubin molecular species
Description: It will determine the concentration of the different molecular species of bilirubin and examine the pattern of increase present in patients with liver cirrhosis who develop hepatic encephalopathy and acute-on-chronic liver failure (ACLF) compared to other groups like patients with liver cirrhosis and healthy people.

Intervention type: DIAGNOSTIC_TEST
Intervention: Liquid Chromatography-Mass Spectrometry Method to identify bilirubin molecular species
Description: It will determine the concentration of the different molecular species of bilirubin and examine the pattern of increase present in patients with liver cirrhosis who develop hepatic encephalopathy and acute-on-chronic liver failure (ACLF) compared to other groups like patients with liver cirrhosis and healthy people.

Intervention type: DIAGNOSTIC_TEST
Intervention: Liquid Chromatography-Mass Spectrometry Method to identify bilirubin molecular species
Description: It will determine the concentration of the different molecular species of bilirubin and examine the pattern of increase present in patients with liver cirrhosis who develop hepatic encephalopathy and acute-on-chronic liver failure (ACLF) compared to other groups like patients with liver cirrhosis and healthy people.

Intervention type: DIAGNOSTIC_TEST
Intervention: Liquid Chromatography-Mass Spectrometry Method to identify bilirubin molecular species
Description: It will determine the concentration of the different molecular species of bilirubin and examine the pattern of increase present in patients with liver cirrhosis who develop hepatic encephalopathy and acute-on-chronic liver failure (ACLF) compared to other groups like patients with liver cirrhosis and healthy people.
Study: NCT06506344

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 5S Trial
Description: Participants will receive caring contacts/recruitment outreach, suicide risk screening, suicide safety planning, and, if indicated, connection to healthcare services, resources and the CLASP virtual outreach intervention.